These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 9159749)

  • 1. Acanthocytosis and spinocerebellar degeneration: a new association?
    Tsai CH; Chen RS; Chang HC; Lu CS; Liao KK
    Mov Disord; 1997 May; 12(3):456-9. PubMed ID: 9159749
    [No Abstract]   [Full Text] [Related]  

  • 2. Parcopa: a rapidly dissolving formulation of carbidopa/levodopa.
    Med Lett Drugs Ther; 2005 Jan; 47(1201):12. PubMed ID: 15706700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective treatment with levodopa and carbidopa for hypomyelination with atrophy of the basal ganglia and cerebellum.
    Wakusawa K; Haginoya K; Kitamura T; Togashi N; Ishitobi M; Yokoyama H; Higano S; Onuma A; Nara T; Iinuma K
    Tohoku J Exp Med; 2006 Jun; 209(2):163-7. PubMed ID: 16707859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
    Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
    Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case report: successful use of rectally administered levodopa-carbidopa.
    Cooper SD; Ismail HA; Frank C
    Can Fam Physician; 2001 Jan; 47():112-3. PubMed ID: 11212422
    [No Abstract]   [Full Text] [Related]  

  • 6. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A case presenting clinical features of spinocerebellar degeneration with dentatorubral tract involvement in MRI. Clinical conference].
    Kumagai T
    No To Shinkei; 2003 Aug; 55(8):723-30. PubMed ID: 13677309
    [No Abstract]   [Full Text] [Related]  

  • 8. Mechanisms involved in the control of extrapyramidal dysfunctions and in striatal dopamine synthesis.
    Goldstein M; Anagnoste B; Battista AF; Miyamoto T; Fuxe K
    Adv Neurol; 1974; 5():79-85. PubMed ID: 4374069
    [No Abstract]   [Full Text] [Related]  

  • 9. [Advanced course of Parkinson disease. Little improved motion with continuous intestinal levodopa administration].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 2005 Jul; 28(7):245-6. PubMed ID: 16038123
    [No Abstract]   [Full Text] [Related]  

  • 10. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
    Fleming SM; Delville Y; Schallert T
    Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbidopa/levodopa-responsive myoclonus.
    Fitzgerald DB; Drago V; Sutherland D; Heilman KM
    Mov Disord; 2007 Feb; 22(3):392-5. PubMed ID: 17216651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing pathological gambling in Parkinson's disease with enteral levodopa/carbidopa infusions.
    Gerschlager W; Bloem BR
    Mov Disord; 2009 Sep; 24(12):1858-60. PubMed ID: 19514056
    [No Abstract]   [Full Text] [Related]  

  • 13. Levodopa-responsive rubral (Holmes') tremor.
    Vélez M; Cosentino C; Torres L
    Mov Disord; 2002 Jul; 17(4):741-2. PubMed ID: 12210864
    [No Abstract]   [Full Text] [Related]  

  • 14. Adrenoleukodystrophy manifesting as spinocerebellar degeneration.
    Mishra S; Modi M; Das CP; Prabhakar S
    Neurol India; 2006 Jun; 54(2):195-6. PubMed ID: 16804268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydrocephalic parkinsonism due to Paget's disease of bone: dramatic improvement following ventriculoperitoneal shunt and temporary levodopa/carbidopa therapy.
    Ikeda K; Kinoshita M; Aoki K; Tomatsuri A
    Mov Disord; 1997 Mar; 12(2):241-2. PubMed ID: 9087985
    [No Abstract]   [Full Text] [Related]  

  • 16. [Neuroimaging of spinocerebellar degeneration].
    Kojima S
    No To Shinkei; 1995 Jan; 47(1):35-42. PubMed ID: 7669399
    [No Abstract]   [Full Text] [Related]  

  • 17. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
    Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
    Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease.
    Nausieda PA; Pfeiffer RF; Tagliati M; Kastenholz KV; DeRoche C; Slevin JT
    Clin Ther; 2005 Jan; 27(1):58-63. PubMed ID: 15763606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Augmentation of artistic productivity in Parkinson's disease.
    Walker RH; Warwick R; Cercy SP
    Mov Disord; 2006 Feb; 21(2):285-6. PubMed ID: 16261619
    [No Abstract]   [Full Text] [Related]  

  • 20. [The use of Stalevo in Hungary for patients with Parkinson disease and its effect on the quality of life].
    Klivényi P; Vécsei L
    Ideggyogy Sz; 2008 Jan; 61(1-2):42-8. PubMed ID: 18372774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.